Annals of Oncology最新文献

{"title":"48P Epitranscriptomic liquid biopsy: A new paradigm for early detection and management of gastrointestinal cancers","authors":"A. Martinec, A. Amalric, A. Bastide, S. Govindaswamy, K. Brunel, A. Attina, S. Garcia-Llorens, J. Vialaret, O. Scholler, S. Quesada, C. Hirtz, E. Rivals, A. David","doi":"10.1016/j.annonc.2026.05.050","DOIUrl":"10.1016/j.annonc.2026.05.050","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 ","pages":"Page S19"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148523440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"99P Comparison of two ddPCR-based analyses for MRD in the OPTIMISE trial (NCT04680260)","authors":"L.B. Callesen, T.F. Hansen, R.F. Andersen, N. Pallisgaard, S. Kramer, S. Schlander, S.R. Rafaelsen, M. Mau-Sorensen, T.M. Smedman, J. Smeby, A.K. Boysen, L.H. Jensen, A.K. Jakobsen, K-L.G. Spindler","doi":"10.1016/j.annonc.2026.05.100","DOIUrl":"10.1016/j.annonc.2026.05.100","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 ","pages":"Page S38"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148523600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Title Page","authors":"","doi":"10.1016/S0923-7534(26)00922-1","DOIUrl":"10.1016/S0923-7534(26)00922-1","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 ","pages":"Page iv"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148529610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"107P Impact on efficacy of neutropenia, G-CSF use and dose modifications in patients with metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil + bevacizumab (FTD/TPI+BEV): Maximising bias-reduction","authors":"I. Baraibar Argota, M. Guerra González, F. Salvà Ballabrera, F.J. Ros Montana, N. Moreno Pena, C. Salvà, M. Rodriguez Castells, R. Comas, A. Aguilera, L. Rivera Sanchez, A. Farriols, N. Saoudi Gonzalez, A. Garcia Rodriguez, A. Alcaraz, C. Martínez Soler, G. Villacampa, M.Q. Gorgas Torner, J. Tabernero, M-J. Carreras Soler, E. Elez Fernandez","doi":"10.1016/j.annonc.2026.05.108","DOIUrl":"10.1016/j.annonc.2026.05.108","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 ","pages":"Pages S41-S42"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148529698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"76P Next-generation sequencing testing rates, timeliness, and guideline concordance in patients with metastatic colorectal cancer","authors":"S.M. Marini, D. Antonio, M.J. Gurley, G. Rodriguez","doi":"10.1016/j.annonc.2026.05.077","DOIUrl":"10.1016/j.annonc.2026.05.077","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 ","pages":"Pages S28-S29"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148531448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"60P Multi-centre real-world experience of neoadjuvant ipilimumab/nivolumab for locally advanced mismatch repair deficient colon cancer","authors":"N.C. Ramchander, K.S. Shohdy, C. Crearie, C. McKeeve, G. Naylor, L.J. Rodgers, A. McKillop, A.A. Malik, D. Storey, R.H. Wilson, M. White, J.S. Graham","doi":"10.1016/j.annonc.2026.05.062","DOIUrl":"10.1016/j.annonc.2026.05.062","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 ","pages":"Pages S23-S24"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148531561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"31P Tumour laterality and survival in colorectal cancer: A five-year retrospective cohort study from a high-volume oncology centre in Sub-Saharan Africa","authors":"E.A. Aje, C.I. Agbakwuru, A. Sowunmi, B.C. Adegboyega, B. Oshikanlu, F. Aina-Tolofari, M. Bashir, M. Habeebu, E.T. Andero","doi":"10.1016/j.annonc.2026.05.034","DOIUrl":"10.1016/j.annonc.2026.05.034","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 ","pages":"Pages S13-S14"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148531807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"39P Clinical and survival differences between Lynch syndrome and sporadic MSI early-onset colorectal cancer: Results from the SECOC consortium","authors":"A. Puccini, M. Marti, R. Vidal Tocino, A. Ballestero, G. Sanz, P. Guarner, A. Maroli, C. Foppa, V. Daprà, M. Bartolini, G. Migliaccio, A. Spinelli, J. Perea García","doi":"10.1016/j.annonc.2026.05.042","DOIUrl":"10.1016/j.annonc.2026.05.042","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 ","pages":"Pages S16-S17"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148532090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"OPTIMAL: a multinational phase III study of oral paclitaxel (DHP107) versus intravenous weekly paclitaxel in HER2-negative recurrent or metastatic breast cancer","authors":"B. Xu,&nbsp;H. Jeong,&nbsp;T. Sun,&nbsp;J. Sohn,&nbsp;Q. Zhang,&nbsp;S. Kostic,&nbsp;X. Wang,&nbsp;Z. Tong,&nbsp;S. Wang,&nbsp;J. Wang,&nbsp;W. Li,&nbsp;K.S. Lee,&nbsp;Y.W. Moon,&nbsp;M.J. Kang,&nbsp;X. Hu,&nbsp;T.Y. Kim,&nbsp;D. Milenković,&nbsp;J.H. Seo,&nbsp;J.H. Kim,&nbsp;J. Lee,&nbsp;S.-B. Kim","doi":"10.1016/j.annonc.2026.03.002","DOIUrl":"10.1016/j.annonc.2026.03.002","url":null,"abstract":"<div><h3>Background</h3><div>Intravenous (i.v.) paclitaxel (Taxol) requires prolonged infusion and is associated with hypersensitivity reactions and peripheral neuropathy. This study evaluated the efficacy and safety of DHP107, a novel oral formulation of paclitaxel, compared with i.v. paclitaxel in patients with HER2-negative, recurrent, or metastatic breast cancer.</div></div><div><h3>Patients and methods</h3><div>This multinational, multicenter, open-label, randomized phase III trial evaluated the noninferiority of DHP107 compared with i.v. paclitaxel, with a predefined noninferiority margin of 1.33. Eligible patients had recurrent or metastatic breast cancer and had received no prior chemotherapy in the metastatic setting. Patients were randomly assigned to receive either DHP107 (200 mg/m² orally twice daily on days 1, 8, and 15) or paclitaxel (80 mg/m² i.v. on days 1, 8, and 15) in a 28-day cycle. The primary endpoint was investigator-assessed progression-free survival (PFS) in the per-protocol set (PPS). Secondary endpoints included independent central review-assessed PFS, overall survival (OS), tumor response, quality of life, and safety.</div></div><div><h3>Results</h3><div>Between January 2018 and December 2023, 549 patients were randomly assigned to receive either DHP107 (<em>n</em> = 277) or paclitaxel (<em>n</em> = 272); 519 patients were included in the PPS. DHP107 demonstrated noninferiority in PFS with a median PFS of 10.0 months compared with 8.5 months for paclitaxel (hazard ratio [HR] 0.869; 95% confidence interval [CI] 0.707-1.068). The median OS was 32.6 months for DHP107 and 31.8 months for paclitaxel (HR 0.967, 95% CI 0.762-1.227). DHP107 was associated with higher rates of neutropenia, febrile neutropenia, nausea, diarrhea, and vomiting, whereas peripheral neuropathy and hypersensitivity reactions were more common with paclitaxel. No treatment-related death occurred in the DHP107 group, and one (0.4%) in the paclitaxel group. Quality of life was comparable between the two groups.</div></div><div><h3>Conclusions</h3><div>DHP107 demonstrated noninferior efficacy compared with i.v. paclitaxel, with a manageable safety profile, supporting its use as an effective and convenient alternative in HER2-negative breast cancer.</div></div>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 7","pages":"Pages 936-945"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147462664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re-evaluating antibody–drug conjugate linker stability: assessment, interpretation, and clinical translation","authors":"R. Colombo,&nbsp;S.D. Seredick,&nbsp;S.D. Barnscher,&nbsp;J.R. Rich","doi":"10.1016/j.annonc.2026.04.008","DOIUrl":"10.1016/j.annonc.2026.04.008","url":null,"abstract":"<div><div>Antibody–drug conjugates (ADCs) have emerged as an important class of anticancer therapeutics. Their highly modular design offers multiple opportunities to refine their properties and improve clinical performance by tuning individual components, including the antibody, linker, and payload.</div><div>Recent ADC optimization efforts have focused on more stable linker designs, apparently based on the assumption that premature payload release, rather than ADC uptake and intracellular catabolism, is the primary driver of off-target toxicity and limited antitumor activity. However, clinical data highlight a more complex picture.</div><div>Several clinically successful ADCs employ relatively unstable linkers, including some with short systemic half-lives. In contrast, ADCs with increased linker stability have not consistently demonstrated improved clinical outcomes and, in many cases, have been associated with unexpected toxicities.</div><div>In this article, we examine common assumptions regarding ADC linker stability, highlight limitations of preclinical models in predicting human payload exposure, address appropriate methods to assess ADC stability, and discuss the clinical implications of altering ADC linker stability. By re-evaluating the role of linker stability in ADC design, this review aims to inform more rational strategies for the development of next-generation ADCs.</div></div>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 7","pages":"Pages 902-919"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147760282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}